Virometix, a Schlieren, Switzerland-based biotechnology company, raised CHF1.2m in in an extension to its recent Series A financing round.
Furthermore, the company announced the appointment of senior executive Harry Welten, MBA as new independent member of its Board of Directors. He will replace Prof. John Robinson, who stepped down from the Board of Directors earlier this year to now support the company as a member of the Scientific Advisory Board.
The additional funds will be used to further speed up development of its vaccine candidates for Respiratory Syncytial Virus (RSV) and cancer immunotherapy.
Led by Arin Ghasparian, CEO, and Pierre Morgon, Chairman, Virometix is a biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic human diseases.
The company is developing a portfolio of preclinical candidates for a vaccine for Respiratory Syncytial Virus (RSV), two broad-spectrum next-generation vaccines for HPV/cervical cancer and for S. pneumoniae diseases as well as vaccines for the treatment of cancers.